Investor Overview

Corporate Profile

ArTara is focused on identifying and optimizing product candidates for patients suffering from diseases with a significant unmet need. ArTara’s current development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. The Company’s lead program TARA-002 is being developed for the treatment of lymphatic malformations. ArTara’s second program, intravenous (IV) choline chloride, is a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).




Copyright West LLC. Minimum 15 minutes delayed.

btn Stock

IR Tools

  • Printed Materials
  • Email Alerts
  • RSS Feeds
  • Email Page
  • Print

IR Contact

Media Contact

Karen O’Shea, Ph.D.
LifeSci Public Relations
Phone: 929-469-3860

Social icons